The global ventricular fibrillation treatment market is expected to achieve a valuation of USD 9.19 billion in 2023, with strong growth anticipated over the next decade. According to Future Market Insights, the market is projected to expand at a compound annual growth rate (CAGR) of 8.5%, reaching approximately USD 20.78 billion by 2033.
This growth is largely driven by the increasing incidence of ventricular fibrillation, a life-threatening cardiac arrhythmia that requires immediate intervention. Advances in treatment technologies, including improved defibrillation methods and the development of innovative cardiac devices, are also contributing to market expansion.
The rising awareness of cardiac health and the importance of timely treatment for ventricular fibrillation further underscore the need for effective therapeutic solutions. This dynamic market presents significant opportunities for healthcare providers, medical device manufacturers, and research institutions focused on enhancing cardiac care and improving patient outcomes in emergency and critical care settings.
But it is also considered that the high cost of the technologies required in the treatment of the global ventricular fibrillation market is coupled with strict regulations that will hamper the growth of the industry.
Also, there has been a noticeable rise in the number of patients suffering from Ventricular fibrillation is disorderly and irregular electrical activity in the heart’s ventricles. The ventricles, in turn, do not contract and pump blood out of the heart into the body where VFib is an emergency. So, if VFib develops, the body will not receive the blood it needs as the heart is no longer pumping.
The only way to correct a heart that is experiencing VFib is to give it an electrical shock with a defibrillator. If the shock is administered in time, a defibrillator can revert the heart to a normal, healthy rhythm.
Ventricular Fibrillation (VF) Treatment Market Historical Period 2018 To 2022 Demand Analysis Vs. Forecast 2023
The global Ventricular Fibrillation Treatment Market grew at a CAGR of 6.8% from 2018 to 2022, as per Future Market Insights, a provider of market research and competitive intelligence.
Earlier, the most common presentation for VF is sudden collapse from cardiac arrest leading to SCD. This results from improper ventricular contraction resulting in low cardiac output. Patients may demonstrate signs of acute MI such as chest pain, shortness of breath, nausea, and vomiting before the event. Patients with a known history of coronary artery disease or congestive heart failure may show a worsening of chronic symptoms such as angina, dyspnea, orthopnea, paroxysmal nocturnal dyspnea, and pedal edema. At the time of presentation, patients are unconscious, unresponsive, and have no palpable pulse. Without prompt action, this leads to death within the next few minutes. Patients with ICD for primary or secondary prevention can experience shock from ICD firing at the time of experiencing VF.
Nowadays, ICDs can reduce the risk of sudden cardiac death by the development of an entirely subcutaneous ICD (S-ICD) system with efficacy similar to that of conventional ICD in terminating VF which has been a major advance in device technology. Although randomized comparative data are not yet available, pooled data from the EFFORTLESS and IDE trials have shown the S-ICD to be a safe and effective alternative to conventional transvenous ICDs- especially in younger patients with HCM, genetic channelopathies, and adult complex congenital heart disease.
How Competitive Is the Market for Ventricular Fibrillation (VF) Market Treatment?
Some of the prominent players in the global market for VF treatment are
- CardioDx, Inc.
- Advanced Instrumentations Inc.
- Cameron Health, Inc.
- Bexen Cardio
- CU Medical Systems, Inc.
- Biotronik SE & Co. KG
- Pfizer Inc.
- Heritage Pharmaceuticals Inc.
- Baxter International Inc.
- Lawson Health Research Institute
Some of the important developments of the key players in the market are
In March 2021, the Rankin government announced that all public schools in Nova Scotia would be provided with automated external defibrillators. The government invested US$ 700,000.
In February 2022, Medtronic said that Freezor and Freezor Xtra Cardiac Cryoablation Focal Catheters, the first and only ablation catheters licensed to treat the rising prevalence of juvenile Atrioventricular Nodal Reentrant Tachycardia, had obtained FDA extended approval (AVNRT).
Key Companies Profiled
- CardioDx, Inc.
- Advanced Instrumentations Inc.
- Cameron Health, Inc.
- Bexen Cardio
- CU Medical Systems, Inc.
- Biotronik SE & Co. KG
- Pfizer Inc.
- Heritage Pharmaceuticals Inc.
- Baxter International Inc.
- Lawson Health Research Institute
Key Segments Profiled in the Respiratory Distress Syndrome Management Market Report
Diagnostic techniques:
- Electrocardiogram
- Blood Test
- Echocardiogram
- Electrophysiology Study
- X-ray
Treatment:
- CPR
- Defibrillation
- Medication
- Catheter ablation
- Left cardiac sympathetic denervation
Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East & Africa
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
